NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Rocket Companies, Inc. (NYSE:RKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://www.zlk.com/pslra-1/rocket-companies-inc-loss-submission-form?prid=149725&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your NET Power, Inc. (NYSE:NPWR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/net-power-inc-lawsuit-submission-form?prid=149726&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 22, 2025 / If you suffered a loss on your Canopy Growth Corporation (NASDAQ:CGC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/canopy-growth-corporation-lawsuit-submission-form?prid=149727&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq.

Advance Auto Parts maintained its outlook for the year while reporting better-than-expected results in its latest quarter.

Office REITs like ONL are deeply out of favor, but supply-demand dynamics and low new construction support a bullish long-term thesis. ONL's Q1 2025 shows slight occupancy improvement, but high capital expenditures and negative dividend coverage remain for now. Management is aggressively leasing and selling assets, but it is coming at a price.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay.

Shares of BJ's Wholesale Club Holdings Inc. BJ-1.33% are up 0.4% in premarket trades after the membership-based warehouse retailer maintained its full-year guidance, despite fiscal first-quarter revenue and comparable sales that missed Wall Street's expectations.

REITs have been in the penalty box for nearly 3.5 years now. This has opened up some highly compelling opportunities in the sector. I share my top 2 high-yield REIT picks right now.

SCOTTSDALE, Ariz., May 22, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network dedicated to revolutionizing access to chiropractic care and building a leading wellness franchise with a strong business model, announced Christopher M.

MMC's roll-up strategy, highlighted by the McGriff acquisition, has driven impressive scale, recurring revenue, and margin expansion in the insurance brokerage sector. Consistently high returns on equity and invested capital, well above peers, demonstrate MMC's durable competitive advantages and management's capital allocation skill. Valuation remains reasonable relative to historical ranges, despite significant improvements in margins and returns, making MMC attractive for long-term investors.

Revenue of $2.64 billion, with double-digit year-over-year growth across all end markets Operating cash flow of $3.9 billion and free cash flow of $3.3 billion on a trailing twelve-month basis or 39% and 34% of revenue, respectively Returned $0.7 billion to shareholders via dividends and repurchases during the second quarter WILMINGTON, Mass. , May 22, 2025 /PRNewswire/ -- Analog Devices, Inc. (Nasdaq: ADI), a global semiconductor leader, today announced financial results for its fiscal second quarter 2025, which ended May 3, 2025.

NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elevance Health, Inc. ("Elevance" or "the Company") (NYSE:ELV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Elevance securities between April 18, 2024 and October 16, 2024, both dates inclusive (the "Class Period").

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces that it has received a notice from Nasdaq confirming that the Company has regained compliance with The Nasdaq's Capital Market's minimum bid price requirement of $1.00 per share and the minimum stockholders' equity requirement of $2.5 million.

AUSTIN, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Accelsius , a leader in two-phase, direct-to-chip liquid cooling, has been selected as a key contributor to a U.S. Department of Energy (DOE) ARPA-E COOLERCHIPS project led by Professor Dereje Agonafer, a Presidential Distinguished Professor and Member of the National Academy of Engineering, at The University of Texas at Arlington. The project, “Holistic Co-Design of Novel Hybrid Cooling Technology for the Data Center of the Future,” will develop a next-generation hybrid architecture that combines direct-to-chip evaporative cooling with air-based solutions such as rear door heat exchangers.

LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences.

SALT LAKE CITY, Utah, May 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramics for medical device and other technical applications, announced the issuance of International Patent No. 7635292, which covers novel agricultural uses of the Company's silicon nitride (Si₃N₄) particularly in plant protection and antimicrobial treatment. This patent, combined with issued U.S. Patent No. 11,591,217, creates a family of patents focused on addressing the antimicrobial agribiotech market.

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases

• BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete • Full commercial infrastructure for launch in place ahead of July 22nd PDUFA date • Conference call today at 8:00 AM ET WOBURN, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2025 and provided a business update.

CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that preclinical data assessing combinations of Sionna's nucleotide-binding domain 1 (NBD1) stabilizers, SION-451 and SION-719, with complementary Sionna CFTR modulators, galicaftor (SION-2222) and SION-109, will be featured in an oral presentation at the European Cystic Fibrosis Society's (ECFS) 48th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy.